SECUKINUMAB
DrugBank ID: db09029
DrugCentral: secukinumab
Synonymous : None
Drug Sentece Context
Table 1. Analysis of context sentence of secukinumab gene in 12 abstracts.
| pmid | sentence |
|---|---|
| 32510244 | In light of the current Covid-19 pandemic and the ongoing, extensive debate about the use of biological agents in psoriatic patients, we felt compelled to relate our experience in the use of secukinumab in the same cohort before and during the lockdown in Italy. Areas covered: Secukinumab was not discontinued, and there were no cases of confirmed infection with SARS-CoV-2 in this cohort. Expert opinion: In our practice, there is no evidence favoring the discontinuation of secukinumab in these patients. |
| 32512263 | Two patients had a mild infection, and 2 developed severe COVID-19 related respiratory complications, including 1 patient on secukinumab requiring mechanical ventilation and 1 patient on rituximab developing viral pneumonia requiring supplemental oxygenation. […] Six patients were on secukinumab with 1 hospitalization. […] Rituximab or secukinumab could worsen the viral disease. |
| 32591970 | The aim of the current article is to review the growing body of knowledge on the course/management of COVID-19 in patients with inflammatory rheumatic diseases by presenting a SARS-CoV-2 infected case with ankylosing spondylitis under secukinumab therapy. […] A 61-year old patient with ankylosing spondylitis who was on secukinumab therapy for 5 months admitted with newly onset fever and gastrointestinal complaints. […] The literature search revealed four articles reporting the clinical course of COVID-19 in seven rheumatic patients on secukinumab. |
| 32618402 | One of the secukinumab patients also presented a relatively good outcome. |
| 33002515 | Capsule summary (33 of 35 words; 2 of 2 sentences): Secukinumab reduced the inflammation and the expression of ACE2, which encodes the SARS-CoV-2 receptor, in plaques of patients with psoriasis. […] Reductions in ACE2 expression with secukinumab significantly correlated with reductions in disease activity. |
| 33131470 | The results of the first randomized studies on the use of inhibitors of pro-inflammatory cytokines and chemokines (interleukin-6 (tocilizumab), interleukin-17 (secukinumab), Janus kinase blockers, through which the signal is transmitted to cells (ruxolitinib)), which have potential in the early treatment of COVID- 19. […] The design of the original COLORIT comparative study on the use of colchicine, ruxolitinib and secukinumab in the treatment of COVID-19 is presented. |
| 33369063 | All patients had been receiving a biological agent including ustekinumab, etanercept, adalimumab, secukinumab, infliximab, ixekizumab, or certolizumab pegol. |